CRISPR Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results

-Enrollment ongoing in clinical trials of CTX001™ for patients with severe hemoglobinopathies- -Enrollment ongoing in clinical trial of CTX110 ™ , targeting CD19+ malignancies- -Began treating patients in clinical trial of CTX120™, targeting B-cell maturation antigen (BCMA)- -IND and CTA approved